Personensuche
X
?
1
First-Time Disclosure of CVN424, a Potent and Selective GPR..:
Huikai Sun (2037619) ; Holger Monenschein (1822072) ; Hans H. Schiffer (10660697)...
https://figshare.com/articles/dataset/First-Time_Disclosure_of_CVN424_a_Potent_and_Selective_GPR6_Inverse_Agonist_for_the_Treatment_of_Parkinson_s_Disease_Discovery_Pharmacological_Validation_and_Identification_of_a_Clinical_Candidate/14439413. , 2021
https://figshare.com/articles/dataset/First-Time_Disclosure_of_CVN424_a_Potent_and_Selective_GPR6_Inverse_Agonist_for_the_Treatment_of_Parkinson_s_Disease_Discovery_Pharmacological_Validation_and_Identification_of_a_Clinical_Candidate/14439413. , 2021
?
2
Discovery of TAK-041: a Potent and Selective GPR139 Agonist..:
Holly A. Reichard (2115589) ; Hans H. Schiffer (10660697) ; Holger Monenschein (1822072)...
https://figshare.com/articles/dataset/Discovery_of_TAK-041_a_Potent_and_Selective_GPR139_Agonist_Explored_for_the_Treatment_of_Negative_Symptoms_Associated_with_Schizophrenia/14983813. , 2021
https://figshare.com/articles/dataset/Discovery_of_TAK-041_a_Potent_and_Selective_GPR139_Agonist_Explored_for_the_Treatment_of_Negative_Symptoms_Associated_with_Schizophrenia/14983813. , 2021
?
3
Discovery of TAK-041: a Potent and Selective GPR139 Agonist..:
Holly A. Reichard (2115589) ; Hans H. Schiffer (10660697) ; Holger Monenschein (1822072)...
https://figshare.com/articles/journal_contribution/Discovery_of_TAK-041_a_Potent_and_Selective_GPR139_Agonist_Explored_for_the_Treatment_of_Negative_Symptoms_Associated_with_Schizophrenia/14983816. , 2021
https://figshare.com/articles/journal_contribution/Discovery_of_TAK-041_a_Potent_and_Selective_GPR139_Agonist_Explored_for_the_Treatment_of_Negative_Symptoms_Associated_with_Schizophrenia/14983816. , 2021
?
4
First-Time Disclosure of CVN424, a Potent and Selective GPR..:
Huikai Sun (2037619) ; Holger Monenschein (1822072) ; Hans H. Schiffer (10660697)...
https://figshare.com/articles/journal_contribution/First-Time_Disclosure_of_CVN424_a_Potent_and_Selective_GPR6_Inverse_Agonist_for_the_Treatment_of_Parkinson_s_Disease_Discovery_Pharmacological_Validation_and_Identification_of_a_Clinical_Candidate/14439410. , 2021
https://figshare.com/articles/journal_contribution/First-Time_Disclosure_of_CVN424_a_Potent_and_Selective_GPR6_Inverse_Agonist_for_the_Treatment_of_Parkinson_s_Disease_Discovery_Pharmacological_Validation_and_Identification_of_a_Clinical_Candidate/14439410. , 2021
1-4